SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (3402)2/22/2019 1:40:11 AM
From: tuck   of 3661
 
Trillium (TRIL) off nearly 40% after hours as the much anticipated and probably front run offering comes. $15 million at 80 cents/share - which is where the price is now. Trillium's fumble with dosing really cost it, as competitors have cropped up, and at least one alleged therapeutic advantage (the lack of RBC binding) doesn't seem to be as big as originally thought. So they've dawdled their way from being a leader in the CD47 space to being an also ran penny stock.

Could this be the bottom? Maybe. But that's a big speculation to make with this management team. Maybe Merck will buy them :>)

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News